Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting date of February 2, 2016. The filing addresses a critical corporate governance event regarding the company's stock listing status on The NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock price thresholds rather than financial performance metrics.
Material Changes
- Delisting Notice: On February 2, 2016, the company received formal notice from NASDAQ that its Common Stock would be subject to delisting.
- Non-Compliance: The company failed to regain compliance with NASDAQ Listing Rule 5450(a)(1) (the "Bid Price Rule"), which requires a minimum closing bid price of $1.00 per share for 10 consecutive business days.
- Timeline: The company had previously transferred its listing to the NASDAQ Capital Market to secure an extension until February 2, 2016, but was unable to meet the price requirement by this deadline.
Outlook, Risks, and Management Commentary
- Management Action: The company intends to timely request a hearing before the NASDAQ Listing Qualifications Panel to present a plan for compliance and request a further extension.
- Potential Extension: The Panel has discretion to grant up to an additional 180 calendar days (until August 1, 2016) to satisfy the Bid Price Rule.
- Immediate Effect: The request for a hearing will automatically stay any delisting action pending a final decision.
- Risk Disclosure: There is no assurance that the Panel will grant the request for continued listing. If denied, the stock will be delisted from NASDAQ.
Investor Verification Checklist
- Verify the current trading status of the stock on NASDAQ following the hearing request.
- Review the press release filed as Exhibit 99.1 (dated February 5, 2016) for specific details on the compliance plan.
- Monitor the outcome of the hearing before the NASDAQ Listing Qualifications Panel.
- Check subsequent filings for any updates on the stock's bid price performance.